Company profile · Lachen, Switzerland

Octapharma

Plasma Proteins, Recombinant Therapeutics, and Global Biopharma Supply · Global biologics manufacturing and supply

Octapharma strengthens the Swiss therapeutics spine with a live official CEO disclosure and a visible industrial plasma-products profile.

Lead
Wolfgang Marguerre (verified ↗)
Address
Seidenstrasse 2, 8853 Lachen SZ, Switzerland (source ↗)
Compliance
GMP plasma-product manufacturing
Last reviewed
14 Mar 2026 (3mo ago)
Scale
Global biologics manufacturing and supply
Capabilities
Plasma Fractionation · Recombinant Product Supply · Commercial Biopharma Operations
Founded
1983
Headcount
10000+
LinkedIn
Company page (open ↗)
Site and address
Clinical profileSTATUS: VERIFIED MARCH 2026

Wolfgang Marguerre

Chairman and Chief Executive Officer

Check official leadership source
Full addressSeidenstrasse 2, 8853 Lachen SZ, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source

Official Octapharma privacy statement listing Seidenstrasse 2, 8853 Lachen SZ.

Open source
Operating profile

Global biologics manufacturing and supply

Lachen, Switzerland. Plasma Proteins, Recombinant Therapeutics, and Global Biopharma Supply. Review completed on 14 Mar 2026.

2026 technical specializationPlasma Proteins, Recombinant Therapeutics, and Global Biopharma Supply
Core capabilities
Plasma FractionationRecombinant Product SupplyCommercial Biopharma Operations
Governance

Swiss, EMA, FDA, and global biologics oversight

GMP plasma-product manufacturing, Global biologics quality systems

Editorial note

Plasma Proteins, Recombinant Therapeutics, and Global Biopharma Supply

Octapharma strengthens the Swiss therapeutics spine with a live official CEO disclosure and a visible industrial plasma-products profile.

Related companies
Editorial note

Octapharma strengthens the Swiss therapeutics spine with a live official CEO disclosure and a visible industrial plasma-products profile.

FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026Last reviewed: 14 March 2026
Capabilities

Core capabilities

Primary declared technical activities and areas of operating focus.

Plasma Fractionation
Recombinant Product Supply
Commercial Biopharma Operations
Verification source dossier

Verification source dossier

Official source set used to support leadership, physical-site, certification, and watch-note evidence.

Leadership evidenceOctapharma official about page confirming Wolfgang Marguerre as Chairman and CEO.Source origin: octapharma.comOpen source
Supporting evidenceOctapharma official company surface describing plasma and recombinant product operations.Source origin: octapharma.comOpen source
Physical-site evidenceOfficial Octapharma privacy statement listing Seidenstrasse 2, 8853 Lachen SZ.Source origin: octapharma.comOpen source
Infrastructure

Declared infrastructure

Plasma-product manufacturing systems
Quality-control laboratories
Commercial supply platforms
Regulatory posture

Quality system coverage

GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.

GMP
VERIFIED ACTIVE 2026
GLP
REVIEW IN PROGRESS 2026
ISO-13485
REVIEW IN PROGRESS 2026
FDA-Inspected
REVIEW IN PROGRESS 2026
Verification history

Verification history

14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ

Frequently asked questions

Where is Octapharma located?
Octapharma operates from Seidenstrasse 2, 8853 Lachen SZ, Switzerland, Lachen, Switzerland.
Who runs Octapharma?
Octapharma is led by Wolfgang Marguerre, Chairman and Chief Executive Officer. Verified 14 Mar 2026.
What certifications does Octapharma hold?
Octapharma is documented under GMP plasma-product manufacturing.
What does Octapharma do?
Octapharma strengthens the Swiss therapeutics spine with a live official CEO disclosure and a visible industrial plasma-products profile. Core capabilities: Plasma Fractionation, Recombinant Product Supply, Commercial Biopharma Operations.
Editorial context

Related technical briefs

Briefs that name Lachen as a covered market or city.